US Patent 8,435,944: Scope, Claims, Expiration, Litigation and Testosterone Patent Landscape

US Patent 8,435,944 protects a specific method of delivering testosterone through the axillary skin without a patch. Its core combination is a testosterone-containing, non-occlusive liquid composition applied to at least one axilla, with more than 60% lower alcohol, a specified penetration enhancer, a viscosity-modifying agent, and dosing sufficient to raise testosterone to at least 200 ng/dL.

The patent is method-of-treatment protection, not a broad composition patent. Its commercial relevance is closely associated with axillary testosterone products such as Axiron. The principal design-around routes are use of a non-axillary site, a patch or occlusive system, a different penetration enhancer, alcohol at 60% or less, or a formulation outside the claimed viscosity range.

What does US Patent 8,435,944 protect?

US 8,435,944 protects methods for increasing testosterone blood levels in adult men by applying a defined transdermal testosterone formulation to at least one axilla. The patent issued May 7, 2013, from the Acrux transdermal testosterone development program. Eli Lilly commercialized Axiron under a license from Acrux.[1][2]

The independent claims are claims 1 and 13. Both require the following core elements:

Limitation	Claims 1 and 13
Patient	Adult male subject in need of treatment
Therapeutic objective	Increase testosterone blood level
Application site	At least one axilla
Delivery system	Non-occlusive transdermal composition
Patch exclusion	Applied without occlusion by a patch device
Active ingredient	Pharmaceutically effective amount of testosterone
Alcohol	Lower alkyl alcohol exceeding 60% v/v
Penetration enhancer	Specified enhancer group
Rheology component	One or more viscosity-modifying agents
Optional components	Water, activator, antiperspirant or deodorant
Pharmacodynamic result	Testosterone blood level of at least 200 ng/dL

The independent claims do not require a particular commercial product name, pump design, testosterone concentration, application volume, dosing frequency or brand.

How do claims 1 and 13 differ?

Claim 1 has the broader penetration-enhancer Markush group. It covers glycols, oleic acid, isopropyl myristate, cyclopentadecanone, sorbitan monooleate, octisalate, octyldimethyl-para-aminobenzoate, octyl para-methoxycinnamate and combinations.

Claim 13 narrows the enhancer group to three sunscreen-related enhancers:

Octisalate
Octyldimethyl-para-aminobenzoate
Octyl para-methoxycinnamate

Claim 13 also expressly requires that the viscosity modulator raise viscosity above that of water but below 300 centipoise.

Issue	Claim 1	Claim 13
Alcohol threshold	More than 60% v/v	More than 60% v/v
Enhancer group	Broad nine-category group	Narrow three-category group
Viscosity range	Added only in dependent claims	Required directly
Optional antiperspirant/deodorant	Yes	No express requirement
Main commercial significance	Broad formulation and method coverage	Axiron-like viscosity and enhancer profile

What do the dependent claims add?

Claims 2 through 12 and 14 through 21 create narrower positions around androgen deficiency, alcohol concentration, enhancer identity, viscosity and excipient concentration.

Alcohol concentration

Claims 3, 4, 12 and 16 through 18 progressively require ethanol, isopropanol or mixtures at:

More than 60% v/v under the independent claims
More than 70% v/v under claims 3, 12 and 17
More than 80% v/v under claims 4 and 18

A formulation at exactly 60%, 70% or 80% does not satisfy the literal “more than” threshold. A formulation above the threshold may be exposed even if its precise alcohol percentage differs from the commercial product.

Penetration enhancers

Claims 5, 6, 10, 11 and 14 through 15 narrow the enhancer limitation.

The most important species are:

Octisalate
Isopropyl myristate
Octyldimethyl-para-aminobenzoate
Octyl para-methoxycinnamate

Claims 6 and 15 specifically protect octisalate. Claims 10 and 14 require enhancer concentration of 0.01% to 15% w/v.

Viscosity modifiers

Claims 7 through 9 and 19 through 20 focus on:

Polyvinyl pyrrolidone, or PVP
Hydroxypropyl methyl cellulose
Viscosity greater than water and less than 300 cP
PVP concentration of 1% to 3% w/v

The PVP claims are commercially important because they tie the method to a formulation that is more viscous than a simple hydroalcoholic solution but remains spreadable and pumpable.

What is the likely claim scope under literal infringement analysis?

A competing product would generally need to satisfy every limitation of an asserted claim. For claim 1, the patent owner would need to establish that the accused method involves:

An adult male subject.
A therapeutic need to increase testosterone.
Application to at least one axilla.
No occlusion by a patch device.
A non-occlusive transdermal composition.
Testosterone in a pharmaceutically effective amount.
More than 60% lower alcohol by volume.
At least one listed penetration enhancer.
A viscosity-modifying agent.
Application producing at least 200 ng/dL testosterone.

A product may avoid literal infringement by changing any one of these elements. The most commercially practical alternatives are changing the application site, using an occlusive patch, reducing alcohol to 60% or less, removing a listed enhancer, or adopting a formulation with no qualifying viscosity modifier.

The “consisting of” transition is significant. It generally excludes unlisted components that materially alter the claimed composition, subject to claim-construction principles and the treatment of incidental ingredients. The claims also use “optionally” for several components, so the absence of water, an activator, an antiperspirant or a deodorant does not by itself avoid infringement.

What formulations are protected by US 8,435,944?

The strongest formulation coverage is concentrated around a high-alcohol, low-to-moderate-viscosity, axillary testosterone solution.

A high-risk formulation profile would include:

Formulation characteristic	Risk under the patent
Testosterone active	Required
Ethanol or isopropanol above 60% v/v	High
Octisalate	High
PVP at 1% to 3% w/v	High
Viscosity above water and below 300 cP	High
Application to axilla	Required
Patch-free delivery	Required
Blood testosterone at least 200 ng/dL	Required result

A formulation using testosterone, ethanol above 70%, octisalate and PVP is particularly close to the narrower dependent claims. A formulation using isopropyl myristate rather than octisalate remains within claim 1 and is specifically addressed by claims 10 through 12.

When does US Patent 8,435,944 lose exclusivity?

The patent’s ordinary 20-year term is tied to the earliest effective nonprovisional filing date in its US priority chain. Public patent records identify an August 2004 priority date, placing the expected US expiration in August 2025, subject to any applicable patent-term adjustment.[3]

Event	Date
Earliest reported priority	August 2004
US patent grant	May 7, 2013
Expected ordinary term end	August 2025
Patent-term extension	No material extension is generally associated with this patent
Post-expiration status	Method claims cease to block conduct occurring after expiration

Patent expiration does not eliminate other Axiron-related patents. A generic or follow-on manufacturer must review the complete Orange Book listing and the broader patent family, including any continuation or formulation patents with later expiration dates.

What is the Orange Book status of Axiron and related testosterone products?

Axiron was approved by the FDA as a testosterone topical solution for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone.[2] The product uses axillary administration and is supplied in a metered pump.

The Orange Book framework is relevant because an ANDA applicant referencing Axiron must address listed patents through Paragraph I, II, III or IV certifications. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed.

The relevant regulatory distinction is:

Axiron: NDA product and reference-listed drug.
Generic testosterone topical solution: ANDA product referencing the Axiron formulation and route.
AndroGel, Testim, Fortesta and Vogelxo: separate testosterone products with different formulation, application-site and patent profiles.
Androderm: transdermal patch product, generally outside the literal axillary non-occlusive method claimed by US 8,435,944.

Orange Book listings can change through delisting, patent expiration or FDA administrative updates. The patent number must therefore be evaluated against the current Orange Book entry and the full Axiron patent set rather than in isolation.[4]

Which companies challenged Axiron patent protection?

Axiron faced generic competition after ANDA filings for testosterone topical solution. The principal commercial challengers associated with generic testosterone topical solution included Perrigo and other generic manufacturers pursuing FDA approval.

The litigation risk centered on whether an ANDA product, its proposed labeling and expected use would practice the axillary, non-occlusive, high-alcohol testosterone method. The relevant disputes could involve:

Infringement based on the proposed ANDA label.
Validity of the formulation and method claims.
Obviousness based on earlier testosterone gels and transdermal delivery systems.
Written-description and enablement arguments concerning the blood-level limitation.
Patent-term timing and settlement-based launch rights.

A generic applicant can avoid some method claims through a modified label or a formulation that omits a required element. That strategy is less effective where the product’s labeled use, dosage instructions and formulation collectively track the patented method.

What Paragraph IV challenges and settlement risks exist?

A Paragraph IV challenge creates potential litigation under the Hatch-Waxman framework. If the NDA holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to statutory exceptions and court developments.[5]

For US 8,435,944, the major legal questions in a Paragraph IV case would be:

Obviousness

The challenger would likely combine known testosterone replacement therapy, hydroalcoholic topical delivery, penetration enhancers and viscosity control. The patent owner would respond that axillary delivery, the specific alcohol concentration, enhancer selection, viscosity range and blood-level result provide a non-obvious combination.

Claim construction

The parties could dispute:

The meaning of “non-occlusive.”
Whether a deodorant applicator or metered pump is a “patch device.”
How “combined volume” of lower alcohols is calculated.
Whether the viscosity range is measured before or after application.
Whether the 200 ng/dL limitation is a treatment result or a required method step.
The scope of “pharmaceutically effective amount.”

Induced infringement

The treatment-result limitation makes labeling important. Instructions that direct axillary use of the relevant formulation may support an induced-infringement theory even where the manufacturer does not perform the treatment itself.

How strong is the patent estate?

US 8,435,944 has moderate commercial strength but limited platform breadth.

Strength factor	Assessment
Clear commercial association	Strong
Product-specific relevance	Strong for axillary hydroalcoholic solutions
Composition claim protection	Limited because claims are methods
Geographic reach	US only
Design-around flexibility	Meaningful
Dependence on patient use	High
Vulnerability to obviousness attack	Material
Post-expiration value	None for this patent

The patent is stronger against a close Axiron substitute than against unrelated testosterone gels, patches or injectables. Its claim architecture provides multiple fallback positions through alcohol percentage, enhancer identity and PVP concentration. Its principal weakness is that a competitor can potentially avoid infringement without abandoning testosterone replacement therapy.

How does this patent compare with competing testosterone products?

Product category	Application site	Delivery format	Exposure to US 8,435,944
Axiron-type solution	Axilla	Non-occlusive liquid	Highest
AndroGel-type gel	Shoulders/upper arms	Gel	Generally lower
Fortesta-type gel	Thighs	Gel	Generally lower
Testim/Vogelxo-type gel	Shoulders/upper arms	Gel	Generally lower
Androderm	Skin site under patch	Occlusive patch	Lower under the patch exclusion
Injectable testosterone	Intramuscular or subcutaneous	Injection	Outside claim scope
Oral testosterone	Oral	Capsule/tablet	Outside claim scope

The patent is therefore a route-and-formulation patent, not a monopoly over testosterone replacement therapy.

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest litigation-risk route for a product that would otherwise practice the claims. The manufacturer can launch after the patent’s August 2025 ordinary term, subject to other unexpired patents and regulatory requirements.

At-risk launch after Paragraph IV litigation

A generic company may launch before patent expiration after prevailing in litigation, securing a favorable settlement, or accepting litigation exposure. The commercial risk depends on damages, injunction prospects, market share and whether other patents remain enforceable.

Design-around launch

A manufacturer may seek approval for a product using:

A non-axillary administration site.
A different delivery system.
Alcohol concentration at or below 60% v/v.
An unlisted penetration enhancer.
No qualifying viscosity-modifying agent.
A label that does not direct the claimed axillary method.

Design-around products must still satisfy FDA bioavailability, pharmacokinetic, labeling and safety requirements.

What manufacturing and IP barriers remain?

The patent does not claim manufacturing steps. It therefore does not directly block manufacture of testosterone, ethanol, PVP or the listed enhancers. Commercial barriers arise from formulation reproducibility and regulatory equivalence.

Relevant technical barriers include:

Maintaining a homogeneous testosterone solution.
Controlling viscosity within the claimed range.
Achieving consistent pump metering.
Managing ethanol evaporation.
Preserving dose uniformity during storage.
Demonstrating sufficient transdermal absorption through axillary skin.
Preventing transfer to other individuals.
Establishing a testosterone exposure profile comparable to the reference product.

The manufacturing process may be covered by separate patents, trade secrets, know-how or regulatory exclusivity, even when US 8,435,944 itself is not a process patent.

What is the geographic coverage?

US 8,435,944 has territorial effect only in the United States. Corresponding applications or patents in Europe, Australia, Canada and other jurisdictions must be reviewed separately. Foreign family members may have different claim sets, prosecution histories, expiration dates and legal status.

A global freedom-to-operate analysis should separate:

US method claims.
Foreign transdermal-delivery claims.
Product and formulation patents.
Manufacturing patents.
Regulatory exclusivity.
Trademark and branding rights.

Key Takeaways

US 8,435,944 covers a method of raising testosterone levels through axillary application of a non-occlusive, patch-free testosterone composition.
The core formulation requires more than 60% lower alcohol, a listed penetration enhancer and a viscosity-modifying agent.
Claims 3, 4, 17 and 18 strengthen protection at alcohol levels above 70% and 80%.
Claims 6, 15 and 19 through 20 create narrower positions around octisalate and PVP.
The patent is closely aligned with Axiron-type testosterone topical solution.
It does not broadly cover all testosterone gels, patches, injections or oral products.
The expected ordinary expiration is August 2025, subject to patent-term calculations.
Generic risk depends on the complete Axiron patent estate, not US 8,435,944 alone.
The clearest design-around options are changing the application site, delivery format, alcohol level, penetration enhancer or viscosity system.
The patent has stronger blocking value against an Axiron substitute than against other testosterone replacement products.

FAQs

Does US 8,435,944 claim Axiron itself?

No. It claims methods of using a defined testosterone formulation. Axiron is a branded product associated with the claimed axillary, non-occlusive delivery approach.

Can a testosterone gel applied to the shoulders infringe this patent?

Ordinarily, no, because the claims require application to at least one axilla. A separate patent could still cover the shoulder-delivery formulation or method.

Does using a pump instead of a patch avoid the patent?

Not by itself. The claims exclude occlusion by a patch device, but they do not require or exclude a particular pump. A pump-delivered axillary solution can fall within the claims.

Is testosterone blood concentration of 200 ng/dL a mandatory claim limitation?

Yes. The independent claims require application in an amount effective to achieve at least 200 ng/dL. The evidentiary treatment of that result would depend on claim construction and the facts of the accused method.

Does patent expiration eliminate FDA requirements for a generic testosterone solution?

No. Patent expiration removes the patent barrier but does not replace the need for FDA approval, appropriate labeling, manufacturing compliance and bioequivalence or other applicable regulatory evidence.

References

United States Patent and Trademark Office. (2013). U.S. Patent No. 8,435,944, Transdermal delivery of testosterone.
U.S. Food and Drug Administration. (2011). Axiron (testosterone) topical solution prescribing information. Eli Lilly and Company.
United States Patent and Trademark Office. (n.d.). Patent term examination data and patent-family records for U.S. Patent No. 8,435,944.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
21 U.S.C. § 355(j). Abbreviated applications for new drugs and patent certifications.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	AXIRON	testosterone	SOLUTION, METERED;TRANSDERMAL	022504-001	Nov 23, 2010		DISCN	Yes	No	8,435,944	⤷ Start Trial				A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2005902902	Jun 03, 2005

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006254742	⤷ Start Trial
Australia	2011202787	⤷ Start Trial
Brazil	PI0611134	⤷ Start Trial
Canada	2610708	⤷ Start Trial
China	101212975	⤷ Start Trial
China	102091079	⤷ Start Trial
Eurasian Patent Organization	019214	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,435,944

Which drugs does patent 8,435,944 protect, and when does it expire?

Summary for Patent: 8,435,944